

# Ali Raza Khaki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4624311/publications.pdf>

Version: 2024-02-01

69  
papers

2,363  
citations

516215

16  
h-index

223531

46  
g-index

70  
all docs

70  
docs citations

70  
times ranked

5687  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.   | 6.3 | 1,395     |
| 2  | Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.   | 3.4 | 149       |
| 3  | Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.            | 7.7 | 108       |
| 4  | Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.                 | 2.0 | 70        |
| 5  | Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , 2019, 7, e191-e199.                                   | 2.9 | 53        |
| 6  | Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis. <i>American Journal of Hypertension</i> , 2014, 27, 801-810.                       | 1.0 | 49        |
| 7  | Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.  | 2.8 | 43        |
| 8  | Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2021, 11, 9029.    | 1.6 | 39        |
| 9  | A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.                      | 2.6 | 39        |
| 10 | Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.   | 0.2 | 32        |
| 11 | Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2134330.  | 2.8 | 32        |
| 12 | Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. <i>JAMA Network Open</i> , 2022, 5, e2216183.                          | 2.8 | 27        |
| 13 | The Macroscopic Rate of Nucleic Acid Translocation by Hepatitis C Virus Helicase NS3h Is Dependent on Both Sugar and Base Moieties. <i>Journal of Molecular Biology</i> , 2010, 400, 354-378.         | 2.0 | 26        |
| 14 | A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.                        | 7.7 | 26        |
| 15 | Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2022, 128, 1194-1205. | 2.0 | 26        |
| 16 | Evaluation of a Resident-Led Project to Decrease Phlebotomy Rates in the Hospital: Think Twice, Stick Once. <i>JAMA Internal Medicine</i> , 2016, 176, 708.   | 2.6 | 22        |
| 17 | Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.   | 1.3 | 18        |
| 18 | Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. <i>Bladder Cancer</i> , 2020, 6, 71-81.   | 0.2 | 16        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. <i>The Lancet Healthy Longevity</i> , 2022, 3, e143-e152.   | 2.0 | 16        |
| 20 | Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154. | 0.9 | 13        |
| 21 | Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e266-e276.  | 0.9 | 12        |
| 22 | LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). <i>Annals of Oncology</i> , 2020, 31, S1202-S1203.  | 0.6 | 11        |
| 23 | Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.   | 0.9 | 10        |
| 24 | Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.   | 2.8 | 9         |
| 25 | Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. <i>Cancer</i> , 2020, 126, 4446-4450.   | 2.0 | 7         |
| 26 | Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 227.   | 3.4 | 7         |
| 27 | Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. <i>JCO Oncology Practice</i> , 2021, 17, e1728-e1737.  | 1.4 | 7         |
| 28 | Time intervals between U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1575-1575.   | 0.8 | 7         |
| 29 | Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population. <i>JCO Oncology Practice</i> , 2021, 17, 583-586.  | 1.4 | 7         |
| 30 | Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. <i>Targeted Oncology</i> , 2020, 15, 541-548.  | 1.7 | 6         |
| 31 | Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. <i>JCO Oncology Practice</i> , 2020, 16, e1543-e1552.   | 1.4 | 6         |
| 32 | Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 39-39.  | 0.8 | 6         |
| 33 | Association of treatment type with patient-reported quality of life in cancer distress screening.. <i>Journal of Clinical Oncology</i> , 2021, 39, 178-178.  | 0.8 | 6         |
| 34 | Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 732.e9-732.e16.                       | 0.8 | 6         |
| 35 | Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16007-e16007.  | 0.8 | 6         |
| 36 | Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 443-443.                        | 0.8 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. <i>Cancer Investigation</i> , 2021, 39, 1-6.   | 0.6 | 4         |
| 38 | Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab193.  | 0.4 | 4         |
| 39 | Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124728.   | 2.8 | 4         |
| 40 | Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.                      | 0.9 | 4         |
| 41 | Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2021, 7, 33-42.   | 0.2 | 3         |
| 42 | Perioperative Immunotherapy in Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 131-133.  | 2.6 | 3         |
| 43 | Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. <i>Blood</i> , 2020, 136, 56-58.         | 0.6 | 3         |
| 44 | Association of prior local therapy and outcomes with programmed cell death ligand-1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.   | 1.3 | 3         |
| 45 | Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021. <i>BJU International</i> , 2022, 129, 168-170.   | 1.3 | 3         |
| 46 | Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e1-273.e9.                   | 0.8 | 3         |
| 47 | Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 445-445.            | 0.8 | 2         |
| 48 | Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1456-1458.               | 2.3 | 2         |
| 49 | Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. <i>Cancer Investigation</i> , 2022, 40, 17-25.   | 0.6 | 2         |
| 50 | Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. <i>Cancer Investigation</i> , 2021, 39, 21-24.  | 0.6 | 1         |
| 51 | Loose Regulatory Standards Portend a New Era of Imprecision Oncology. <i>Cancer Investigation</i> , 2021, 39, 1-4.   | 0.6 | 1         |
| 52 | Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12035-12035.                                 | 0.8 | 1         |
| 53 | Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16515-e16515. | 0.8 | 1         |
| 54 | Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11523-11523.                              | 0.8 | 1         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e1-496.e8.                                    | 0.8 | 1         |
| 56 | Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4525-4525.   | 0.8 | 1         |
| 57 | Nucleic Acid Translocation By Hepatitis C Virus Helicase NS3h Is Dependent on Sugar and Base Moieties. <i>Biophysical Journal</i> , 2010, 98, 12a.  | 0.2 | 0         |
| 58 | 771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. <i>Annals of Oncology</i> , 2020, 31, S594.  | 0.6 | 0         |
| 59 | Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 406-406.   | 0.8 | 0         |
| 60 | Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20.. <i>Journal of Clinical Oncology</i> , 2021, 39, 22-22.  | 0.8 | 0         |
| 61 | Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 444-444.                               | 0.8 | 0         |
| 62 | Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 419-419.                 | 0.8 | 0         |
| 63 | Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16526-e16526. | 0.8 | 0         |
| 64 | Response and outcomes to immune checkpoint inhibitors (ICI) in advanced urothelial cancer (aUC) based on prior intravesical BCG.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4537-4537.  | 0.8 | 0         |
| 65 | Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020.. <i>Journal of Clinical Oncology</i> , 2021, 39, 135-135.  | 0.8 | 0         |
| 66 | Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16016-e16016.   | 0.8 | 0         |
| 67 | Intensity of end-of-life (EOL) cancer care in Western Washington (WA) versus Alberta (AB), Canada (CA).. <i>Journal of Clinical Oncology</i> , 2019, 37, 89-89.   | 0.8 | 0         |
| 68 | Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada. <i>Blood</i> , 2020, 136, 21-21.  | 0.6 | 0         |
| 69 | Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study. <i>European Urology</i> , 2022, , .               | 0.9 | 0         |